Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone in Refractory AML
NCT00106600Phase 2Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Mar 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of pixantrone in acute myeloid leukemia (AML), sponsored by CTI BioPharma Corp.. Started Mar 2005; status: completed.
02
Drugs
pixantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00106600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00106600.